Treatment of invasive candidiasis in immunocompromised pediatric patients

Pediatric Drugs

Volumn 10, Issue 5, 2008, Pages 281-298

  Fisher, Brian T ^a   Zaoutis, Theoklis E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Albaconazole, pharmacodynamics; Albaconazole, pharmacokinetics; Amphotericin B, pharmacodynamics; Amphotericin B, pharmacokinetics; Amphotericin B, therapeutic use; Azoles, therapeutic use; Candidiasis, treatment; Echinocandins, pharmacokinetics

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; COLONY STIMULATING FACTOR; CYCLOSPORIN; CYCLOSPORIN A; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POLYENE; POSACONAZOLE; PYRROLE; RAPAMYCIN; RAVUCONAZOLE; TACROLIMUS; VINBLASTINE; VINCRISTINE; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BLURRED VISION; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CANDIDA; CARDIOVASCULAR DISEASE; CHILD; CHILL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION RESISTANCE; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; PHOTOPHOBIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TORSADE DES POINTES; VISUAL DISORDER; VOMITING;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; DRUG COMBINATIONS; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 50649089818     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810050-00003     Document Type: Review

References (205)

1. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999 May; 28 (5): 1071-9
2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993 May; 167 (5): 1247-51
3. Muller FM, Groll AH, Walsh TJ. Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Eur J Pediatr 1999 Mar; 158 (3): 187-99
4. Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988 Feb; 11 Suppl. A: 411-26
5. Fisher MA, Talbot GH, Maislin G, et al. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989 Nov; 87 (5): 547-52
6. Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966 Jun; 19 (6): 667-87
7. Gruhn JG, Sanson J. Mycotic infections in leukemic patients at autopsy. Cancer 1963 Jan; 16: 61-73
8. Casazza AR, Duvall CP, Carbone PP. Infection in lymphoma: histology, treatment, and duration in relation to incidence and survival. JAMA 1966 Aug 29; 197 (9): 710-6
9. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease: a study of 364 cases. Am J Med 1977 May; 62 (5): 731-42
10. Myerowitz RL, Pazin GJ, Allen CM. Disseminated candidiasis: changes in incidence, underlying diseases, and pathology. Am J Clin Pathol 1977 Jul; 68 (1): 29-38
11. DeGregorio MW, Lee WM, Linker CA, et al. Fungal infections in patients with acute leukemia. Am J Med 1982 Oct; 73 (4): 543-8
12. Wingard J. Bone marrow to blood stem cells: past, present, future. In: Ezzone S, Schmit-Pokorny K, editors. Bone marrow and stem cell transplantation. 3rd ed. Sudbury: Jones and Barlett Publishers, Inc., 2007: 1-27
13. Young RC, Bennett JE, Geelhoed GW, et al. Fungemia with compromised host resistance: a study of 70 cases. Ann Intern Med 1974 May; 80 (5): 605-12
14. Maksymiuk AW, Thongprasert S, Hopfer R, et al. Systemic candidiasis in cancer patients. Am J Med 1984 Oct 30; 77 (4D): 20-7
15. Kovacicova G, Spanik S, Kunova A, et al. Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand J Infect Dis 2001; 33 (5): 367-74
16. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992 Mar; 14 Suppl. 1: S120-5
17. Strickland-Marmol LB, Vincent AL, Laartz BW, et al. Candidemia in cancer and bone marrow transplant patients: a 10-year retrospective analysis. Infect Med 2004 Jan; 21: 37-42
18. Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004 Jul 15; 39 Suppl. 1: S7-S10
19. Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001 Jul; 45 (7): 2129-33
20. Vigouroux S, Morin O, Moreau P, et al. Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. Haematologica 2006 May; 91 (5): 717-8
21. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982 Jan; 72 (1): 101-11
22. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 Mar 15; 34 (6): 730-51
23. el-Mahallawy HA, Attia I, Ali-el-Din NH, et al. A prospective study on fungal infection in children with cancer. J Med Microbiol 2002 Jul; 51 (7): 601-5
24. Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004 Jul; 23 (7): 635-41
25. Zaoutis TE, Foraker E, McGowan KL, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005 Aug; 52 (4): 295-8
26. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003 Aug; 22 (8): 686-91
27. Abelson JA, Moore T, Bruckner D, et al. Frequency of fungemia in hospitalized pediatric inpatients over 11 years at a tertiary care institution. Pediatrics 2005 Jul; 116 (1): 61-7
28. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000 Nov; 26 (9): 999-1004
29. Dutcher JD. The discovery and development of amphotericin B. Dis Chest 1968 Oct; 54: Suppl. 1: 296-8
30. Holt RJ. Progress in antimycotic chemotherapy 1945-1980. Infection 1980; 8 Suppl. 3: S284-7
31. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004 Feb; 24 (2 Pt 2): 4S-28S, quiz 9S-32S
32. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005 Jun; 52 (3): 895-915, viii
33. Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resist Updat 2005 Aug; 8 (4): 235-45
34. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007 Oct; 55 (4): 287-99
35. Tollemar J, Klingspor L, Ringden O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect 2001; 7 Suppl. 2: 68-79
36. Turnidge JD, Gudmundsson S, Vogelman B, et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994 Jul; 34 (1): 83-92
37. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001 Aug; 21 (8 Pt 2): 133S-48S
38. Ellis M. Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? Transpl Infect Dis 2000 Jun; 2 (2): 51-61
39. Klepser ME. Antifungal resistance among Candida species. Pharmacotherapy 2001 Aug; 21 (8 Pt 2): 124S-32S
40. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002 Apr; 50 (4): 243-60
41. Hamilton-Miller JM. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev 1973 Sep; 37 (3): 166-96
42. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002 Feb; 49 Suppl. 1: 7-10
43. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000 Aug; 46 (2): 171-9
44. Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998 Oct; 42 (10): 2645-9
45. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995 Aug; 39 (8): 1696-9
46. Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997 Nov; 41 (11): 2471-9
47. Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003 Apr; 48 (1): 225-35
48. Niimi K, Maki K, Ikeda F, et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother 2006 Apr; 50 (4): 1148-55
49. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in non-albicans Candida species. Drug Resist Updat 1999 Feb; 2 (1): 9-14
50. Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 Suppl. 1: 119-28
51. Butler WT, Bennett JE, Alling DW, et al. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964 Aug; 61: 175-87
52. Aoun M. Standard antifungal therapy in neutropenic patients. Int J Antimicrob Agents 2000 Oct; 16 (2): 143-5
53. Starke JR, Mason Jr EO, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987 Apr; 155 (4): 766-74
54. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000 Apr; 30 (4): 653-7
55. Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000 May-Jun; 22 (3): 242-6
56. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 Jun; 26 (6): 1383-96
57. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005 Feb; 24 (2): 167-74
58. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998 Sep; 27 (3): 603-18
59. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001 Feb; 20 (2): 77-82
60. Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985 Apr; 151 (4): 704-10
61. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997 Sep; 98 (3): 711-8
62. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 Mar 11; 340 (10): 764-71
63. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998 Oct; 103 (1): 205-12
64. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000 Nov; 31 (5): 1155-63
65. Lass-Florl C. Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial. Expert Rev Anti Infect Ther 2007 Dec; 5 (6): 929-32
66. Graybill JR, Tollemar J, Torres-Rodriguez JM, et al. Antifungal compounds: controversies, queries and conclusions. Med Mycol 2000; 38 Suppl. 1: 323-33
67. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex versus amphotericin B for the treatment of invasive candidiasis: a prospective, randomized, multicenter trial [abstract no. LM21]. 35th Interscience Conference on Antimicrobial Agents Chemotherapy; 1995 Sep 17-20; San Francisco, 330
68. Kennedy MS, Deeg HJ, Siegel M, et al. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983 Mar; 35 (3): 211-5
69. AmBisome® [package insert]. San Dimas (CA): Gilead Sciences, Inc., 2002
70. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957 Mar 30; 179 (4561): 663-6
71. Tassel D, Madoff MA. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine: a new antifungal agent. JAMA 1968 Oct 21; 206 (4): 830-2
72. Bennet JE. Flucytosine. Ann Intern Med 1977 Mar; 86 (3): 319-21
73. Polak A, Grenson M. Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans. Eur J Biochem 1973 Jan 15; 32 (2): 276-82
74. Vermes A, Math t RA, van der Sijs IH, et al. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. Ther Drug Monit 2000 Dec; 22 (6): 676-87
75. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002 Nov; 46 (11): 3518-21
76. Pfaller MA, Diekema DJ, Procop GW, et al. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007 Mar; 45 (3): 796-802
77. Anaissie EJ, Karyotakis NC, Hachem R, et al. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994 Aug; 170 (2): 384-9
78. Graybill JR, Najvar LK, Holmberg JD, et al. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother 1995 Apr; 39 (4): 924-9
79. Medoff G, Kobayashi GS. Strategies in the treatment of systemic fungal infections. N Engl J Med 1980 Jan 17; 302 (3): 145-55
80. Pappas PG. Treatment guidelines for candidiasis [presentation]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago
81. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991 Oct; 28 Suppl. B: 27-38
82. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992 Dec; 15 (6): 1003-18
83. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987 Aug; 83 (2): 236-42
84. Smego RA, Jr., Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984 Nov-Dec; 6 (6): 791-801
85. Wingfield HJ. Absence of fungistatic antagonism between flucytosine and cytarabine in vitro and in vivo. J Antimicrob Chemother 1987 Oct; 20 (4): 523-7
86. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004 Mar; 10 Suppl. 1: 1-10
87. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998 Apr; 11 (2): 382-402
88. Antachopoulos C, Walsh TJ. New agents for invasive mycoses in children. Curr Opin Pediatr 2005 Feb; 17 (1): 78-87
89. Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol Ther 1995; 67 (1): 79-100
90. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol 2003 Jun; 11 (6): 272-9
91. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990 Mar-Apr; 12 Suppl. 3: S318-26
92. Arndt CA, Walsh TJ, McCully CL, et al. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988 Jan; 157 (1): 178-80
93. Wildfeuer A, Laufen H, Schmalreck AF, et al. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses 1997 Nov; 40 (7-8): 259-65
94. Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992 Jun; 120 (6): 987-93
95. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. J Clin Microbiol Infect Dis 1994 Apr; 13 (4): 325-9
96. Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy 1995 Jan-Feb; 15 (1): 52-8
97. Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother 1997 Jun; 41 (6): 1392-5
98. Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. J Clin Microbiol Infect Dis 2004 Apr; 23 (4): 256-70
99. Duswald KH, Penk A, Pittrow L. High-dose therapy with fluconazole greater or equal to 800mg per day. Mycoses 1997 Nov; 40 (7-8): 267-77
100. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999 Aug; 43 (8): 1955-60
101. Viscoli C, Castagnola E, Fioredda F, et al. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob Agents Chemother 1991 Feb; 35 (2): 365-7
102. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 Nov 17; 331 (20): 1325-30
103. Nguyen MH, Peacock JE, Jr., Tanner DC, et al. Therapeutic approaches in patients with candidemia: evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995 Dec 11-25; 155 (22): 2429-35
104. Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991 Aug; 91 (2): 142-50
105. Kauffman CA, Bradley SF, Ross SC, et al. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991 Aug; 91 (2): 137-41
106. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998 Nov; 42 (11): 3018-21
107. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000 Sep; 34 (9): 1032-43
108. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003 Mar 1; 36 (5): 630-7
109. Pearson MM, Rogers PD, Cleary JD, et al. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003 Mar; 37 (3): 420-32
110. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 67 (2): 269-98
111. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003 Sep 1; 37 (5): 728-32
112. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthal 2004 Jan; 122 (1): 42-7
113. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2546-53
114. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2166-72
115. Ikeda Y, Umemura K, Kondo K, et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004 Jun; 75 (6): 587-8
116. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004 Mar; 48 (3): 201-5
117. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005 Dec; 43 (12): 5848-59
118. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006 Mar; 44 (3): 819-26
119. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004 Sep 1; 39 (5): 743-6
120. Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002 Apr; 42 (4): 395-402
121. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006 Feb; 46 (2): 235-43
122. Eiden C, Peyriere H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007 May; 41 (5): 755-63
123. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002 Mar; 21 (3): 240-8
124. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003 Mar; 17 (1): 159-91, ix
125. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 6
126. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 Jan 24; 346 (4): 225-34
127. Keating GM. Posaconazole. Drugs 2005; 65 (11): 1553-67, discussion 68-9
128. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006 Jun; 50 (6): 1993-9
129. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003 Sep; 47 (9): 2788-95
130. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. British J Clin Pharmacol 2004 Feb; 57 (2): 218-22
131. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004 Sep; 48 (9): 3543-51
132. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007 Feb; 51 (2): 495-502
133. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006 Feb; 50 (2): 658-66
134. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 Jan 25; 356 (4): 348-59
135. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007 Mar; 51 (3): 812-8
136. Lortholary O, Dannaoui E, Raoux D, et al. In vitro susceptibility to posaconazole of 1903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2007 Sep; 51 (9): 3378-80
137. Vehreschild JJ, Kruger K, Kurzai O, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 2006; 49 Suppl. 1: 42-7
138. Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64 (18): 1997-2020
139. Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol 2000; 38 Suppl. 1: 335-47
140. Fung-Tomc JC, Huczko E, Minassian B, et al. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998 Feb; 42 (2): 313-8
141. Bartroli J, Turmo E, Alguero M, et al. New azole antifungals. 3: synthesis and antifungal activity of 3-substituted-4 (3H)-quinazolinones. J Med Chem 1998 May 21; 41 (11): 1869-82
142. Ramos G, Cuenca-Estrella M, Monzon A, et al. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999 Aug; 44 (2): 283-6
143. Miller JL, Schell WA, Wills EA, et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 2004 Feb; 48 (2): 384-7
144. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006 Dec; 26 (12): 1730-44
145. Venkataramanan R, Zang S, Gayowski T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002 Sep; 46 (9): 3091-3
146. Bates DW, Yu DT. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc) 2003 Oct; 39 (10): 801-13
147. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993 Jan; 6 (1): 1-21
148. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007 Mar; 27 (3): 369-88
149. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997 Nov; 41 (11): 2326-32
150. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000 Feb; 44 (2): 368-77
151. Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006; 78 (4): 161-77
152. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002 Mar; 46 (3): 739-45
153. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005 Oct; 45 (10): 1145-52
154. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004 Mar; 48 (3): 815-23
155. Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004 Jun; 44 (6): 590-8
156. Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005 Feb; 45 (2): 227-33
157. Cancidas® (caspofungin) [package insert]. Whitehouse Station (NJ): Merck & Co, Inc., 2001
158. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005 Nov; 49 (11): 4536-45
159. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005 Aug; 49 (8): 3317-24
160. Benjamin Jr DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006 Feb; 50 (2): 632-8
161. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 Oct; 47 (10): 3149-54
162. Pfaller MA, Messer SA, Boyken L, et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3000 clinical isolates. J Clin Microbiol 2004 Jul; 42 (7): 3117-9
163. Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. Eur J Clin Microbiol 2006 Feb; 44 (2): 324-6
164. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. Eur J Clin Microbiol 2006 Mar; 44 (3): 760-3
165. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Eur J Clin Microbiol 2005 Nov; 43 (11): 5425-7
166. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008 Jan; 46 (1): 150-6
167. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005 Aug; 49 (8): 3264-73
168. Moudgal V, Little T, Boikov D, et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005 Feb; 49 (2): 767-9
169. Laverdiere M, Lalonde RG, Baril JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006 Apr; 57 (4): 705-8
170. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 Sep; 48 (9): 3407-11
171. Chamilos G, Lewis RE, Albert N, et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007 Jun; 51 (6): 2257-9
172. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 Dec 19; 347 (25): 2020-9
173. Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004 Jun; 48 (6): 2021-4
174. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 Sep 30; 351 (14): 1391-402
175. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. J Clin Microbiol Infect Dis 2005 Oct; 24 (10): 654-61
176. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidiasis: a phase III randomised double-blind trial. Lancet 2007 May 5; 369 (9572): 1519-27
177. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007 Oct 1; 45 (7): 883-93
178. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 Jun 14; 356 (24): 2472-82
179. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 Nov 15; 39 (10): 1407-16
180. Zaoutis TE, Jafri H, Huang L, et al. Prospective, multicenter study of caspofungin for treatment of documented fungal infections in pediatric patients. 45th Annual Meeting of the Infectious Disease Society of America; 2007 Oct 4-7, San Diego (CA), 78
181. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: a randomized double-blind trial. Pediatr Infect Dis J. In press
182. European Medicine Agency. Assessment report for mycamine [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/H- 734-en6.pdf [Accessed 2008 July 30]
183. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004 Sep; 6 (3): 110-6
184. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004 Jul; 34 (1): 13-20
185. Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 Sep; 45 (9): 1018-24
186. Mycamine® (micafungin) [package insert]. Deerfield (IL): Astellas Pharma, Inc., 2005
187. Hanson LH, Perlman AM, Clemons KV, et al. Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother 1991 Jul; 35 (7): 1334-7
188. Tunger O, Bayram H, Deperli K, et al. Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. Saudi Medical Journal 2008 May; 29 (5): 728-33
189. Olson JA, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005 Dec; 49 (12): 4895-902
190. Graybill JR, Bocanegra R, Najvar LK, et al. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother 2003 Jul; 47 (7): 2373-5
191. Louie A, Banerjee P, Drusano GL, et al. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole- susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother 1999 Dec; 43 (12): 2841-7
192. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003 May 15; 36 (10): 1221-8
193. Kujath P, Lerch K, Kochendorfer P, et al. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993 Nov-Dec; 21 (6): 376-82
194. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006 Jul 1; 43 (1): 25-31
195. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005 Sep; 49 (9): 3640-5
196. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, et al. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998 Jun; 26 (6): 1270-8
197. Bodey GP, DeJongh D, Isassi A, et al. Hypersplenism due to disseminated candidiasis in a patient with acute leukemia. Cancer 1969 Aug; 24 (2): 417-20
198. Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk res 2005 May; 29 (5): 493-501
199. Sallah S, Semelka RC, Wehbie R, et al. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 1999 Sep; 106 (3): 697-701
200. Blanchard DK, Michelini-Norris MB, Djeu JY. Production of granulocyte-macrophage colony-stimulating factor by large granular lymphocytes stimulated with Candida albicans: role in activation of human neutrophil function. Blood 1991 May 15; 77 (10): 2259-65
201. Roilides E, Holmes A, Blake C, et al. Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995 Apr; 57 (4): 651-6
202. Bodey GP, Anaissie E, Gutterman J, et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993 Oct; 17 (4): 705-7
203. Nemunaitis J. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 1998 Jun; 26 (6): 1279-81
204. Ravindranath Y. Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol 2003 Jan; 15 (1): 23-35
205. Mehta P. The scientific bases of pediatric bone marrow transplant. In: Mehta P, editor. Pediatric stem cell transplantation. 1st ed. Sudbury: Jones and Bartlett Publishers, Inc., 2004: 3-12